These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32440086)

  • 1. Short-Term Efficacy and Safety of Switching from a Latanoprost/Timolol Fixed Combination to a Latanoprost/Carteolol Fixed Combination.
    Inoue K; Piao H; Iwasa M; Ishida K; Tomita G
    Clin Ophthalmol; 2020; 14():1207-1214. PubMed ID: 32440086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term Efficacy and Safety of a Latanoprost/Carteolol Fixed Combination Switched From Concomitant Therapy to in Patients With Primary Open-angle Glaucoma or Ocular Hypertension.
    Inoue K; Shiokawa M; Iwasa M; Ishida K; Tomita G
    J Glaucoma; 2018 Dec; 27(12):1175-1180. PubMed ID: 30234748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the 24-h efficacy and safety of fixed combination carteolol/latanoprost and timolol/latanoprost in patients with primary open-angle glaucoma and ocular hypertension: a prospective crossover study.
    Saito Y; Kizaki J; Wada Y; Shibasaki Y; Kishimoto N; Aihara M
    Jpn J Ophthalmol; 2021 Sep; 65(5):598-607. PubMed ID: 34279749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fixed Combination of Travoprost and Timolol Maleate Reduces Intraocular Pressure in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Prospective Multicenter Open-Label Study.
    Nakano T; Mizoue S; Fuse N; Iwase A; Matsumoto S; Yoshikawa K
    Adv Ther; 2015 Sep; 32(9):823-37. PubMed ID: 26424331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocular hypotensive effects and safety over 3 months of switching from an unfixed combination to latanoprost 0.005%/timolol maleate 0.5% fixed combination.
    Inoue K; Okayama R; Higa R; Sawada H; Wakakura M; Tomita G
    J Ocul Pharmacol Ther; 2011 Dec; 27(6):581-7. PubMed ID: 22011049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapy.
    Inoue K; Fujimoto T; Higa R; Moriyama R; Kohmoto H; Nagumo H; Wakakura M; Tomita G
    Clin Ophthalmol; 2012; 6():771-5. PubMed ID: 22693419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of switching to latanoprost 0.005%-timolol maleate 0.5% fixed-combination eyedrops from an unfixed combination for 36 months.
    Inoue K; Okayama R; Higa R; Tomita G
    Clin Ophthalmol; 2014; 8():1275-9. PubMed ID: 25061275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension.
    Diestelhorst M; Larsson LI;
    Br J Ophthalmol; 2004 Feb; 88(2):199-203. PubMed ID: 14736774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of ocular hypotensive effect and safety 12 months after changing from an unfixed combination to a latanoprost 0.005% + timolol maleate 0.5% fixed combination.
    Inoue K; Okayama R; Higa R; Wakakura M; Tomita G
    Clin Ophthalmol; 2012; 6():607-12. PubMed ID: 22553420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of benzalkonium chloride-free fixed-dose combination of latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.
    Bhagat P; Sodimalla K; Paul C; Pandav SS; Raman GV; Ramakrishnan R; Joshi A; Raut A
    Clin Ophthalmol; 2014; 8():1241-52. PubMed ID: 25061271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure.
    Shin DH; Feldman RM; Sheu WP;
    Ophthalmology; 2004 Feb; 111(2):276-82. PubMed ID: 15019375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to latanoprost 0.005% and timolol 0.5% dosed concomitantly in patients with open-angle glaucoma or ocular hypertension.
    Rhee DJ; Peace JH; Mallick S; Landry TA; Bergamini MV;
    Clin Ophthalmol; 2008 Jun; 2(2):313-9. PubMed ID: 19668722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effect of latanoprost/timolol fixed combination in patients with glaucoma or ocular hypertension: a prospective, observational, noninterventional study.
    Schwenn O; Heckmann B; Guzy C; Miller PJ
    BMC Ophthalmol; 2010 Sep; 10():21. PubMed ID: 20825668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy.
    Konstas AG; Boboridis KG; Kapis P; Marinopoulos K; Voudouragkaki IC; Panayiotou D; Mikropoulos DG; Pagkalidou E; Haidich AB; Katsanos A; Quaranta L
    Adv Ther; 2017 Jan; 34(1):221-235. PubMed ID: 27913991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
    Topouzis F; Melamed S; Danesh-Meyer H; Wells AP; Kozobolis V; Wieland H; Andrew R; Wells D
    Eur J Ophthalmol; 2007; 17(2):183-90. PubMed ID: 17415690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials.
    Fechtner RD; Airaksinen PJ; Getson AJ; Lines CR; Adamsons IA;
    Acta Ophthalmol Scand; 2004 Feb; 82(1):42-8. PubMed ID: 14982045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraocular pressure and safety in glaucoma patients switching to latanoprost/timolol maleate fixed combination from mono- and adjunctive therapies.
    Konstas AG; Bányai L; Blask KD; Väth J; Kozobolis VP; Trüb PR; Tsironi S; Maloutas S; Teus MA; Stewart WC
    J Ocul Pharmacol Ther; 2004 Oct; 20(5):375-82. PubMed ID: 15650512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The signs of ocular-surface disorders after switching from latanoprost to tafluprost/timolol fixed combination: a prospective study.
    Okumichi H; Kiuchi Y; Baba T; Kanamoto T; Naito T; Nakakura S; Tabuchi H; Nii H; Sueoka C; Sugimoto Y
    Clin Ophthalmol; 2017; 11():1175-1181. PubMed ID: 28790802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter, Randomized, Controlled Study Comparing Tafluprost/Timolol Fixed Combination with Latanoprost/Timolol Fixed Combination in Primary Open-Angle Glaucoma and Ocular Hypertension.
    Suzuki K; Otsuka N; Hizaki H; Hashimoto M; Kuwayama Y;
    Adv Ther; 2018 Jun; 35(6):796-808. PubMed ID: 29873009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of switching to travoprost/timolol fixed-combination therapy from latanoprost monotherapy.
    Kashiwagi K
    Jpn J Ophthalmol; 2012 Jul; 56(4):339-45. PubMed ID: 22581454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.